All these rather dismal projections for the share price fail to factor in the very significant pressure on all small and midcap biotechs in the current market. In a more favorable environment we would see a much higher value on the company with a stock price in mid teens by now. Would like to see biotechs back in favor about the time we start to hear about 113 in the summer.
Market Data 
Markets 
AI
